| Radionuclide antisense therapy can combine the advantages of antisense therapy and internal radioactive therapy to improve the therapeutic efficacy.Objective: We used antisense oligonucleotide (ASON) ,sense oligonucleotide (SON) and 125I labeled antisense peptide nucleic acid (125I-asPNA) transfected by liposome to block CerbB-2 expression in the human ovarian epithelial cancer cell lines SKOV3, and to observe its influence on the multiplication of SKOV3.Methods : 1.CerbB-2 antisense peptide nucleic acid was synthesized and labeled with 125I ; 2. according to the different medicine, our experiment was divided into three experimental groups: (1) control group:①SKOV3 cell control group,②liposome control group,③diamminedichloroplatinum (DDP) control group; (2) oligonucleotide and antisense peptide nucleic acid group :①S ON,②A SON,③asPNA,④L-SON,⑤L-ASON; (3) 125I labelled antisense peptide nucleic acid group:①Na125I,②125I-asPNA,③125I-L-asPNA; 3. To detect the expression of CerbB-2 mRNA in SKOV3 by reverse transcription-polymerase chain reaction(RT-PCR); 4. To detect the expression ratio of Her-2 protein in cell and the cell's Apoptosis by flow cytometry. 5. To observe its influence on the multiplication of SKOV3 by MTT.Results: 1. Labelling ratio of 125I-CerbB-2-asPNA was (56.900±4.384) %, radiochemical purity was (87.000±0.990) %, radioactive activity concentration was 3.7 MBq(0.1μCi)/mL, chemical concentration was 5.00μmol/L. 2.The result of RT-PCR indicated the CerbB-2-mRNA gray scale ratio was(1.451±0.019) in SKOV3 cell control group , after 48h treated with 125I-L-CerbB-2-asPNA,SON,ASON,L-SON,L-ASON,DDP, the CerbB-2-mRNA gray scale ratios were (0.687±0.099),(1.039±0.071),(1.079±0.061),(0.984±0.039),(0.970±0.178),(0.979±0.162),their differences were significant (P=0.004,0.009,0.04,0.003,0.045,0.042)compared with SKOV3 cell control group. 3. Flow cytometry indicated that the expression ratio of Her-2 protein in SKOV3 cell control group was ( 98.725±0.6294 )%. After 24h treated with 125I-L-CerbB-2-asPNA the expression ratio of Her-2 in SKOV3 cell lines was(46.195±0.3319)%, its difference was significan(tP=0.001)compared with SKOV3 cell control group. When its doses was 10ul and 20ul, the expression ratio of Her-2 in SKOV3 cell lines was (98.075±0.6541)% and (46.195±0.3319) %,their difference was significant(P=0.001 ).After 24h treated with SON,ASON,L-SON,L-ASON,DDP, the expression ratios of Her-2 in SKOV3 cell lines were (79.215±0.320) %,(60.963±0.863) %,(75.230±0.529) %,(83.940±0.349) %,(54.740±0.531) % , their differences were significant (P=0.001,0.001,0.001,0.027,0.001) compared with SKOV3 cell control group. 4. The flow cytometry consequence demonstrated that apoptosis ratio of SKOV3 cell control group was(0.3133±0.1026)%, after 24h treated with 125I-L-asPNA its apoptosis ratio of cell wa(s0.6633±0.0929)%,their difference was significan(tP=0.043). 5. MTT showed that the absorbance OD of SKOV3 cell control group cultivated on third days was (0.1873±0.0515), and after treated 24h with 125I-L-PNA ,DDP, L-SON,L-ASON, the absorbance OD of SKOV3 cell on third days were (0.102±0.033),(0.026±0.006),(0.090±0.012),(0.082±0.027), compared with SKOV3 cell control group their differences were significant(P=0.012,0.001,0.001,0.001)。Conclusions:1. 125I-L-CerbB-2-asPNA,SON,ASON,L-SON,L-ASON,DDP can depress the CerbB-2 gene expression of the human ovarian epithelial cancer cell lines SKOV3 on the mRNA level.2. 125I-L-CerbB-2-asPNA,SON,ASON,L-SON,L-ASON,DDP can depress the CerbB-2 protein expression of SKOV3.3. 125I-L-CerbB-2-asPNA can promote apoptosis of SKOV34. 125I-L-CerbB-2-asPNA,L-SON,L-ASON can depress the multiplication of SKOV3.
|
PDF Full Text Request